Background
==========

Normal human sex development involves a series of events: sex determination, which is chromosomally established at fertilization (46,XY or 46,XX); differentiation of the gonads into testes or ovaries; and differentiation of internal and external genitalia, which will follow the male pathway in the presence of testicular hormones, or the female pathway in their absence. Factors adversely affecting any stage of these processes can lead to disorders of sex development (DSD), a group of congenital conditions in which the development of the chromosomal, gonadal or anatomical sex is atypical \[[@B1]\].

Partial and mixed gonadal dysgenesis are relatively rare causes of DSD. Individuals with partial gonadal dysgenesis (PGD) are characterized by genital ambiguity due to variable degrees of testicular dysgenesis, absence of syndromic picture and 46,XY karyotype. The histology of dysgenetic testes may vary from gonads with a few tubular structures and predominance of fibrous tissue to those with mild abnormalities, and they may be found bilaterally or associated with streak gonads \[[@B2]\]. The etiology of most cases of PGD is unknown; mutations in *SRY* (*sex determining region Y*) gene are rarely seen \[[@B3]-[@B5]\], and in recent years mutations in *NR5A1* (*Nuclear Receptor Subfamily 5, Group A, Member 1*) gene were found in a few patients \[[@B6]-[@B8]\].

Mixed gonadal dysgenesis (MGD) is the main differential diagnosis for PGD. Individuals with MGD share similar gonadal and genital features, but the karyotype is 45,X/46,XY or its variants (a 45,X cell line and one or more lineages with a normal or structurally abnormal Y chromosome) \[[@B9]\]. The 45,X/46,XY karyotype may also be found in individuals with female phenotype and Turner syndrome (TS), genital ambiguity and ovotesticular DSD (OT DSD, also known as true hermaphroditism), and in male phenotype with infertility. Whatever the phenotype, this mosaic is associated with short stature, dysmorphisms and cardiovascular and renal anomalies, among other congenital and acquired conditions \[[@B10]\].

Structural rearrangements of the Y chromosome, including deletions, ring chromosomes and isochromosomes may lead to different phenotypes. Yp (short arm) deletions including *SRY* gene directly affect testis differentiation leading to streak gonads and a female phenotype, whereas deletions of the long arm, specially involving the Azoospermia Factor regions AZFa, AZFb and AZFc on Yq11 lead to male infertility \[[@B11]\].

Detection of Y chromosome deletions in routine analysis depends on the size of the missing segment, which may range from a whole chromosome arm, that may be visualized using regular cytogenetic techniques, to a single sequence tagged site (STS) that may only be detected by molecular techniques \[[@B12],[@B13]\]. In recent years, evidences of an association between Y microdeletions and 45,X/46,XY mosaicism have been reported in individuals with TS, MGD and infertility, and there are also indications that the instability caused by such deletions might be more significant in germ cells \[[@B12],[@B13]\].

The aim of this work was to investigate the presence of Y chromosome microdeletions in individuals with 45,X/46,XY mosaicism and its variants bearing different phenotypes and also in patients with PGD, in order to verify if the instability of Y chromosome might be one of the causes of such disorders of gonadal differentiation.

Methods
=======

Subjects
--------

Our sample comprised 28 subjects attending a DSD reference service who were divided into two groups, one of patients with PGD (n = 13) and the other of patients with 45,X/46,XY mosaicism or its variants (n = 15).

Inclusion criteria for the group of PGD were 46,XY karyotype; ambiguous genitalia (hypospadias with or without cryptorchidism or typical male genitalia with bilateral cryptorchidism); absence of clinical signs of TS. The presence of one of the following features were also included: a) a streak gonad and a dysgenetic testis; b) two dysgenetic testes; c) a streak gonad or dysgenetic testis and a contralateral testis without evidences of dysgenesis on routine histological analysis or which was not biopsied during surgery due to normal macroscopic appearance; d) hormonal evidence of congenital dysfunction of seminiferous tubules and Sertoli cells (elevated FSH levels detected in the first months of life) when both testes were not biopsied. Data from these patients are shown in Table [1](#T1){ref-type="table"}.

###### 

Clinical data from 15 patients with 46,XY partial gonadal dysgenesis

   **Case**   **Sex assignment**   **Current age (years)**   **Age at first*visit*(months)**   **Urethral meatus**   **Vaginal introitus**   **Right gonad (site,type)**   **Left gonad (site, type)**
  ---------- -------------------- ------------------------- --------------------------------- --------------------- ----------------------- ----------------------------- -----------------------------
      1               M                      14                            0.5                         PS                     \-                       LS, DT                         LS, S
      2               M                      20                             8                          SCR                    \-                       LS, DT                        LS, DT
      3               F                       4                            2.5                     Normal male                \-                       AB, DT                         I, DT
      4               F                      16                            0.2                         SCR                    \-                       AB, DT                         AB, S
     *5*              M                       9                            0.7                    Norrnal male                \-                       I,NB^1^                      I, NB^1^
      6               M                      25                             4                          SCR                    \-                       LS, DT                        LS, DT
      7               F                      19                            204                         SCR                    \-                       AB, DT                        AB, DT
      8               M                      15                             8                      Normal male                \-                        AB, S                        AB, DT
      9               M                      23                            1.7                         PS                     \-                       LS, NB                         I, DT
      10              M                      2.5                          *25*                         PS                     \-                        LS, T                         AB, S
      11              M                      17                             6                          PS                     \-                        I, S                          I, DT
      12              M                       4                             6                          SCR                    \-                        LS, T                        AB, DT
      13              M                      12                            144                         PS                     \-                       LS, DT                        LS, DT

\- absent, + present, *AB* abdominal, *DT* dysgenetic testis, *F* female, *I* inguinal, *LS* labioscrotal, *M* male, *NB* not biopsied, *PER* perineal, *PS* penoscrotal, *S* streak, *SCR* scrotal, *T* testis.

^1^High FSH levels in the first months of life and infancy.

Inclusion criteria for the group with mosaicism were a 45,X/46,XY mosaicism or its variants, regardless of the phenotype. In this group, 11 patients had MGD, one had TS, one had OT DSD, one had typical male genitalia and one had genital ambiguity and palpable gonads in labioscrotal folds, which had not been biopsied, therefore MGD and OT DSD could not be distinguished. Data from these patients are shown in Table [2](#T2){ref-type="table"}.

###### 

Clinical data from 15 patients with 45,X/46,XY mosaicism or its variants

                                         **Case**                                                           **Previous karyotype**                                                     **FISH**                                  **Previous molecular study**   **Phenotype**   **Sex assignment**   **Current age (yrs)**   **Age at first visit (months)**   **Urethral meatus**   **Vaginal introitus**   **Right gonad (site, type)**   **Left gonad (site, type)**
  -------------------------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------ --------------- -------------------- ----------------------- --------------------------------- --------------------- ----------------------- ------------------------------ -----------------------------
                                            1                                                                     45,X/46,XY                                                              \-                                                  \-                     MGD                F                      5                            1                          SCR                    \-                        I, DT                          I, DT
                                            2                                                                     45,X/46,XY                                                              \-                                                  \-                     MGD                F                     23                            4                          PER                    \+                        LS, T                          AB, S
                                            3                                                                     45,X/46,XY                                                              \-                                                  \-                     MGD                F                     20                            3                          SCR                    \-                         I, T                          I, S
                                            4                                                                     45,X/46,XY                                                              \-                                                  \-                     MGD                M                     10                           21                          PEN                    \-                        LS, T                          AB, S
                                            5                                                              45,X/46,X,idic(Y)(p11.2)                     45,X.ish(DXZ1+, DYZ3-)/46,X,idic(Y).ish idic(Y)(p11.2) (DXZI+, DYZ3++)                \-                MGD ? OT DSD?           M                     1.5                          18                          PS                     \-                        LS, NB                        LS, NB
                                            6                                                                45,X/46,X,del(Y)(q12)                                                        \-                                                  \-                     MGD                M                     19                           180                    SCR or PS^1^                \-                        LS, DT                         AB, S
                                            7                                                                     45,X/46,XY                                                              \-                                                  \-                     MGD                M                    1.75                          20                      normal male                \-                      AB, NB^2^                      AB,NB^2^
                                            8                                                                     45,X/46,XY                                                              \-                                                  \-                     MGD                M                      7                           45                          SCR                    \-                        AB, S                          LS, T
                                            9                                                                     45,X/46,XY                                                              \-                                                  \-                     TS                 F                     6.5                          75                     normal female               \+                        AB, S                          AB, S
                                            10                                                                  45,X/46,X,+mar                                       45,X.ish(DXZ1+,DYZ3-)/46,X,+mar.ish der (Y)                           Y + ^3^                   MGD                F                      5                           *3*                         PS                     \-                        LS, T                          AB, S
                                      (DXZ1+, DYZ3+)                                                                                                                                                                                                                                                                                                                                                                                       
                                            11                                                                    45,X/46,XY                                                              \-                                                  \-                     MGD                M                      3                           1.5                         PS                     \-                         I, S                          LS, T
                                            12                                                                    45,X/46,XY                                                              \-                                                  \-                    OTDSD               M                     0.2                          0.1                         SCR                    \-                        LS, T                          AB, O
                                            13                                                                  45,X/46,X,+mar                                        45,X.ish(DXZ1+,DYZ3-)/46,X,+mar.ish der(Y)                           Y + ^3^                   MGD                M                     17                           192                         SCR                    \-                       LS,NB^2^                        AB, S
                                      (DXZ1+, DYZ3+)                                                                                                                                                                                                                                                                                                                                                                                       
                                            14                                            45,X/46,X,idic(Y)(p11.2)/47,X,idic(Y)(p11.2),idic(Y)(p11.2)   45,X.ish(DXZ1+, DYZ3-)/46,X,idic(Y).ish idic(Y)(p11.2) (DXZ1+,DYZ3++)/                                       MGD                F                     1.5                         0.33                         PS                                               LS, T                          AB, S
   47,X,idic(Y),idic(Y).ish idic(Y)(p11.2)(DXZ1+, DYZ3++), idic(Y)(p11.2)(DXZ1+,DYZ3++)                                                                                                                                                                                                                                                                                                                                                    
                                            15                                             45,X/46,X,+mar1/46,X,+mar2/ 47,X,+2mar1/47,X,+mar1,+mar2                45,X.ish(DXZ1+,DYZ3-)/46,X,+mar1.ish dic der(Y)                         Y + ^3^                   MGD                F                     0.2                           1                          SCR                    \-                        LS, T                          I, S
                                     (DXZ1+, DYZ3++)/                                                                                                                                                                                                                                                                                                                                                                                      
                                  46,X,+mar2.ish der(Y)                                                                                                                                                                                                                                                                                                                                                                                    
                                     (DXZ1+, DYZ3+)/                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                              47,X,+mar1. ish dic der(Y)                                                                                                                                                                                                                                                  
                                                                                                                                                                       (DXZ1+, DYZ3++),+mar2.ish der(Y)(DYZ3x1)                                                                                                                                                                                                                                           

*AB* abdominal, *del* deletion, *DT* dysgenetic testis, *F* female, *i* isochromosome, *I* inguinal, *M* male, *mar* marker, *MGD* mixed gonadal dysgenesis, *NB* not biopsied, *O* ovary, *OT DSD* ovotesticular disorder of sex development, *PEN* penile, *PER* perineal, *PS* penoscrotal, *S* streak, *SCR* scrotal, *LS* labioscrotal, *T* testis, *TS* Turner syndrome. ^1^surgery performed before the first visit; ^2^normal testicular macroscopic appearence on surgery; ^3^positive Y chromosome sequences.

In three patients with mosaicism (cases 10, 13 and 15) karyotype initially revealed a marker chromosome, whose origin was elucidated by the presence of Y-specific DNA sequences (*SRY* and *TSPY* genes and the Y-centromeric region DYZ3) and FISH with DXZ1 and DYZ3 probes (Cytocell Ltd., Cambridge, UK). FISH analysis confirmed the presence of the Y centromere in these cases and determined whether the Y chromosome was monocentric or dicentric. Two other patients (cases 6 and 14) had isodicentric Y chromosomes; in these cases, the presence of two centromeres was observed only in FISH analysis.

This study was approved by local Ethics Committee (Comitê de Ética em Pesquisa - Faculdade de Ciências Médicas - UNICAMP) (1065/2010) and informed consent was obtained from all adult **s**ubjects and from the parents/guardians of all child subjects.

Molecular study
---------------

The screening methods used to identify microdeletions were conventional and multiplex polymerase chain reaction (PCR). Genomic DNA was isolated by Proteinase K (Boehringer Mannheim, Germany) lysis and phenol-chloroform extraction.

We investigated 36 STS located in the Y-specific euchromatic region (short arm - Yp, centromere and long arm - Yq), described in Table [3](#T3){ref-type="table"}. In total, 31 primers pairs were distributed in seven different reaction mixes. Five STSs that did not show amplification within mixes prepared for multiplex PCRs were tested separately: DYZ3, TSPY, Y6H35pr, and Y6HPc54pr Y6HP52pr.

###### 

Order and location of STS along the Y chromosome, sequence of the primers used and expected size of the amplified product

    **STS**    **Locus**               **Location**               **Chromosomic region**       **Primer*sense***         **Primer*antisense***     **Lenght of the amplification product (Bp\*)**
  ----------- ----------- -------------------------------------- ------------------------ --------------------------- --------------------------- ------------------------------------------------
     sY14         SRY                2715341-2715810                      p11.31             GAATATTCCCGCTCTCCGGA        GCTGGTGCTCCATTCTTGAG                           472
    sY1301     BV703591              2881785-2882279                      p11.31              GTCTTGTTGCAGCCCATGT         CAAAGGGAGAATAGCAGGC                           495
    Amely-3    BV678972              6737830-6738427                      p11.2              GGTGGGAGAAGGATGTTGTT        AGTCAATCCGAATGGTCAGG                           598
    sY3218     BV704083              7234129-7234319                      p11.2              CTTTTTCGTTGGAGTCTCGC        GCAAAACCCCGTCTCTACAA                           191
    sY1059      G66106              7561835 -- 7562133                   q11.223             GATCATTCTCAAGGGGCTCA        TTGTTGTTGTTGTCATTGTGG                          299
     TSPY      NG022996              9236076-9307357                      p11.2              CGATAGGCCTCCACTTCATA         GATGACATAATGGCGGAG                            1300
     DYZ3         \-                        \-                         Centromérica          ACACATCACAAAGAACTATG        TGAAAACTACACAGNAAGCTG                          1100
     sY81       DYS271              12606410-12606618                     q11.1              AGGCACTGGTCAGAATGAAG        AATGGAAAATACAGCTCCCC                           209
     sY82       DYS272              12838080-12838343                     q11.1              ATCCTGCCCTTCTGAATCTC        CAGTGTCCACTGATGGATGA                           264
   Y6HP35pr     DYS274                      ND                              \-               GGTACACACTCCATCCTGGAC      CTACAGGCTACCTTTTAGGTGG                          226
     sY86       DYS148              13117503-13117820                     q11.1              GTGACACACAGACTATGCTTC       ACACACAGAGCGACAACCCT                           320
     sY84       DYS273              13299428-13299753                     q11.1              AGAAGGGTCTGAAAGCAGGT        GCCTACTACCTGGAGGCTTC                           326
     sY609      G65840              13488371-13488514                     q11.21             CATAGCCCAGAGCAATCCAT        TAGGCATAGGAAGTGGCTGG                           144
     sY88       DYS276              14113358-14113480                     q11.21             TTGTAATCCAAATACATGGGC       CACCCAGCCATTTGTTTTAC                           123
     sY94       DYS279              14790821-14790970                     q11.21             TCATGACAGCCAGGGTATTT       TTTGGACATAGTTTTTTGGTCC                          150
     sY95       DYS280              15053332-15053634                     q11.21             TCCTACAGATGTCCAAAGTGC       GATGAGTGACCCCAGAATTG                           303
     sY182       KAL-Y              15980790-15980914                    q11.221             TCAGAAGTGAAACCCTGTATG      GCATGTGACTCAAAGTATAAGC                          125
     sY97       DYS281              16263633-16263736                    q11.221           AACTTCATCAGTGTTACATCAAGG      TGTGGCATTTTGTTATGTGG                           104
     sY151       KAL-Y              16020619-16020801                    q11.221           AAATCTGTAGTCTCATATCAATCTG   TTACTTGATTTAGCAATAAAAAGG                         183
     sY102      DYS198              17080238-17080455                    q11.221             CACTACCACATTTCTGGTTGG       CGCTGAGTCCATTCTTTGAG                           218
     sY105      DYS201              17866681-17866981                    q11.221             AAGGGCTTCTTCTCTTGCTT        AGGGAGCTTAAACTCACCGT                           301
    Y6D14pr     DYS205                      ND                              \-             GGCTAGGTGCCAGCAAGTAGATCA      GTTCTCTTCCCCTGCATCAAG                          134
     sY117       DS209              19171254-19171515                    q11.221             GTTGGTTCCATGCTCCATAC        CAGGGAGAGAGCCTTTTACC                           262
   Y6PHc54pr      ND                        ND                              \-                  GCAGAAGAGTTCAGC          GTGGAGTGCTGCATTAAAGG                           166
    sY1287      G75509              19491288-19491607                    q11.221             GCAACATAGATGGACCCAGAA       ATAGCAAAGAGCCTCCCAGA                           320
    sY1752     BV682283             20229909-20230117                    q11.222             TCAGTGTGTCACCAAGCAGG        GAGGCAAGTGGACCATCTGT                           209
     sY127      DYS218              20979804-20980078                    q11.222             GGCTCACAAACGAAAAGAAA        CTGCAGGCAGTAATAAGGGA                           274
     sY134      DYS224              21965448-21965750                    q11.222             GTCTGCCTCACCATAAAACG        ACCACTGCCAAAACTTTCAAA                          301
     sY143      DYS231              22387291-22387601                    q11.223             GCAGGATGAGAAGCAGGTAG        CCGTGTGCTGGAGACTAATC                           311
    sY1059      G66106     22822646-22822944; 23252550-23252848          q11.223             GATCATTCTCAAGGGGCTCA        TTGTTGTTGTTGTCATTGTGG                          299
     sY149       DYS1               23725053-23725184                    q11.223             TGTCACACTGCCCTAATCCT        TGGTCATGACAAAAGACGAA                           132
     sY147      DYS232              23882766-23882865                    q11.223             TTTCTCGTTTGATGATCCTAG     TTAATATGAGAATGAGAACAGATGT                        100
   Fr15-Hpr       ND                        ND                              \-              TACCTTGGTTTTGCACCAGACGC     CACCCTCTGTATATGACCTGGC                          313
   Y6HP52pr     DYS239                      ND                              \-               GGAACTGGCAGGATTAGCTTC        GCTCAGAATCTGCGATCAG                           258
    sY1059      G66106              24054410-24054708                    q11.223             GATCATTCTCAAGGGGCTCA        TTGTTGTTGTTGTCATTGTGG                          299
     sY157      DYS240              24284845-24285134                    q11.223             CTTAGGAAAAAGTGAAGCCG        CCTGCTGTCAGCAAGATACA                           285
    sY1191      G73809              24875620-24876004                     q11.23             CCAGACGTTCTACCCTTTCG        GAGCCGAGATCCAGTTACCA                           385
    sY1059      G66106              26726968-26727266                    q11.223             GATCATTCTCAAGGGGCTCA        TTGTTGTTGTTGTCATTGTGG                          299
    sY3168     BV704033             28761338-28761820                     q11.23             GCACCACTGTACTGAAGCATG      TCCCAGCTCACATTGATGATTA                          483

*\*Bp* basepairs.

Multiplex PCR was carried out in a total volume of 26 μL containing 10× PCR buffer, 1.5 mM MgCl2, 1.25 mM dNTPs (deoxyribonucleotide Tri-Phosphate), DMSO (Dimethylsulfoxide) and 0.5 U Taq (Thermus aquaticus) DNA polymerase (Invitrogen, USA) with 200 to 500 ng of genomic DNA. DNAs from males with 46,XY normal karyotype and normal genitalia were used as positive control and the genomic DNAs from females with normal karyotype and genitalia were used as the negative control in each reaction.

The samples were subjected to PCR amplification using initial denaturation for 5 minutes at 94°C, and 35 cycles of 94°C for 30 seconds, annealing step at 58°C for 45 seconds and extension step at 62°C for 2 minute. The final extension time was 5 minutes at 65°C. Conditions for PCR were the same for all seven mixes. We used the GeneAmp PCR System 9700 thermocycler - Applied Biosystem.

Conventional PCRs were used to test five STSs individually and also to confirm apparent deletions in multiplex PCR, discarding the possibility that the absence of amplification was due to some artifact in the multiplex PCR reaction. The PCR was standardized in a reaction with a final volume of 25 μL. Negative and positive reaction controls were the same as described above.

Gel electrophoresis with 3% agarose in 1 × TBE buffer was used for multiplex PCR products; whereas 1% agarose gel was used for conventional PCR products.

An STS was considered absent only after at least two amplification failures in the presence of positive control. To confirm these deletions, two more individual PCRs were performed.

Results
=======

All patients with PGD had positive amplification for every STS, indicating absence of deletions. Figure [1](#F1){ref-type="fig"} illustrates the absence of microdeletions in one of the mixes from patients with PGD.

![**Agarose gel stained with ethidium bromide showing the PCR fragments of MIX 7 and 4. A** -- Five STS were amplification in all patients of DGP group. M -- Molecular weight marker (Ladder 1Kb); B -- Blank; Individuals: 2, 3, 4, 5, 6, 9, 7, 8, 13 e 12 (Table [1](#T1){ref-type="table"}) e 4\* (Table [2](#T2){ref-type="table"}); ♀ -- Female control; ♂ - Male control. **B** -- Absent amplification of STS sY149 for individuals 10 and 6, and no amplification of STS sY127 for individual 6. M -- Molecular weight marker (Ladder 1Kb); B - Blank; Individuals 5\*, 10\*, 12\* (Table [1](#T1){ref-type="table"}) and individuals 10, 1, 9, 3, 6, 2, 5 (Table [2](#T2){ref-type="table"}); ♀ -- Female control; ♂ - Male control.](1471-2350-14-115-1){#F1}

In the group of patients with mosaicism, six out of 15 individuals showed absence of amplification of some STS indicating the presence of microdeletions. Two of them had a 45,X/46,XY karyotype, while in the other four an abnormal Y chromosome had been detected in cytogenetic analysis. All microdeletions were located in the long arm, with different breakpoints. Figure [1](#F1){ref-type="fig"} shows some of these findings. Confirmation of microdeletions detected by multiplex PCR was achieved by two individual PCRs of each STS. Figure [2](#F2){ref-type="fig"} shows the location of the identified deletions for each patient and their position in relation to AZF regions. Two of the nine patients without deletions in the male-specific region on the Y chromosome (MSY) had isodicentric Y chromosomes.

![**Schematic description of microdeletions found in six individuals in the MOS group.** The figure shows the location of identified deletions for each patient and the position of each deletion in relation to the AZFa, AZFb and AZFc regions. = Fragment present. = Fragment absent.](1471-2350-14-115-2){#F2}

Discussion
==========

The Y chromosome evolved from an autosome, and its evolution has been characterized by massive gene decay, the human MSY retains only three percent of the ancestral autosome genes \[[@B14],[@B15]\]. Human Y chromosome has a total length of approximately 60 MB and is composed of two pseudoautosomal regions (PAR1 and PAR2), the euchromatic region, which is rich in testis-specific genes, and the heterochromatic region, containing highly repetitive satellite DNA. The euchromatic region and some of the heterochromatic parts of the Y chromosome are called MSY (male-specific region on the Y chromosome), which comprises 95% of the chromosome's length \[[@B16],[@B17]\]. MSY contains 496 genes, including 51 coding genes, 326 pseudogenes, and 119 non-coding genes (Ensembl Genome Browser version 69, accessed January 2013) \[[@B18]\].

The present study did not detect Y chromosome microdeletions in the 13 subjects with PGD and normal 46,XY karyotype, therefore the hypothesis that abnormalities at the molecular level leading to loss of the Y chromosome in gonadal cell lines play a role in the etiology of this disorder was not supported. To the best of our knowledge, this is the first study to investigate the association between Y chromosome abnormalities and PGD. However, the hypothesis that mosaicism restricted to testis could be one of the causes of this condition could not be entirely discarded, because the loss of the Y chromosome giving rise to a 45,X cell line can occur in the absence of structural abnormalities of the Y chromosome. Furthermore, microdeletions found on gonadal DNA can be absent on peripheral blood lymphocyte DNA \[[@B19]\].

On the other hand, microdeletions were found in six of 15 patients with a 45,X/46,XY karyotype or its variants, all of them with MGD phenotype. Proximal breakpoints inside the AZF region were defined in four of the six carriers of structural Y chromosome abnormalities which had already been detected in routine karyotype. The molecular study of Y-STS not only allowed to refine the breakpoints, but also made it possible to detect the loss of euchromatic regions of this chromosome.

In addition, in two of nine individuals with an apparently normal Y chromosome (cases 8 and 11) the abnormalities were detected only by the molecular techniques. This frequency (2/9) was similar to that observed by Alvarez-Nava *et al.* (2008) (3/11) \[[@B19]\] and lower than that found by Patsalis *et al.* (2005) (4/7) \[[@B12]\]. Taken together, these findings suggest that 9/27 or one in three individuals with 45,X/46,XY and apparently normal Y chromosome may have Y microdeletions.

All alterations identified in the six individuals were located on the Y chromosome long arm at the beginning of Yq11.221 region, where the AZFb region is located, and extending to AZFc. Only in case 8 the deletion was practically limited to the AZFc region. In the four cases in which an abnormal Y chromosome had already been detected, Y-STS testing were not useful to define distal breakpoints, which might be located between the q11-q12 boundary and terminal Yq. In case 11 the analysis of Y-STS showed that the lost fragment was not confined to the heterochromatic region.

The same fragment in the euchromatic region was lost in cases 6 and 15; the deletion starts at STS sY127, located in Yq11.222, and includes 11 STS. In the karyotype of case 6, only a Yq12 deletion was detectable, while in case 15 there were four cell lines containing markers with different Yq sizes. In case 8, two STS were missing (sY157 and sY3168), indicating a breakpoint within Yq11.223. Upon karyotyping, there was an apparently normal Y chromosome. The deletion in case 10 started at sY149 (Yq11.223), with absence of seven STS.

Deletions found in cases 11 and 13 led to loss of 13 and 17 STS, respectively. In patient 11, whose karyotype was 45,X/46,XY, the missing fragment started in sY117 (Yq11.221) and included all subsequent STS. In case 13 the deletion started at STS sY105, also located in Yq11.221; the karyotype had already detected a structural chromosome abnormality with loss of the heterochromatic region Yq12.

In cases 10, 13 and 15, in which there were Y-derived markers, STS study detected the presence of a terminal deletion of the euchromatic region; deletion in case 10 was the smallest, encompassing AZFc and the overlapping region of AZFb and AZFc.

No deletions (including those of Yp) were found in the two subjects with isodicentric Y chromosomes (cases 5 and 14); these chromosomes are often unstable during cell division, resulting in mosaicism with a 45,X line \[[@B20]\]. As the STS analyzed in this study included all the euchromatic region of Yp from the centromere to p11.31, the break in the short arm that originated these isodicentrics may have occurred in the PAR1 region. It has been suggested that a hot spot located in the PAR1 is prone to chromosomal breakage and reunion with generation of isodicentric Y chromosomes \[[@B20]\].

Yq microdeletions with loss of genes specifically expressed in the testis directly contribute to male infertility. AZFc is most often involved, followed by AZFb, and more rarely AZFa \[[@B21]-[@B23]\]. In addition, deletions involving the entire AZFb region or AZFb-c remove a large stretch of Yq chromatin, which may result in more severe disturbance of X-Y chromosome pairing during meiosis than isolated AZFc deletion leading to meiotic breakdown \[[@B24],[@B25]\]. All microdeletions found in our patients with mosaicism were located in AZFb and AZFc regions; their effect on Y chromosome instability is not mediated by the loss of function of genes related to spermatogenesis, but one could speculate that the loss of these large stretch of Yq could also be more dangerous in mitosis than AZFc deletions alone in increasing the risk of mosaicism due to loss of the abnormal Y chromosome.

The mechanism of Y chromosome deletions is accidental homologous recombination between highly similar or identical sequences, which are found in great abundance on this chromosome \[[@B11]\]. Three of our patients (cases 8, 10 and 11) had a breakpoint within regions consisting of palindromes \[[@B26],[@B27]\], which may have contributed to the emergence of these deletions \[[@B26],[@B27]\].

Most genes involved in Y chromosome deletions are expressed specifically in the testes during spermatogenesis, but do not appear to be essential for fertilization or embryogenesis; thus, these deletions does not seem to adversely affect the fertilization results in men whose sperm was obtained by testicular sperm extraction (TESE). Thus, subjects with MGD may also benefit from procedures such as TESE followed by *in vitro* fertilization with intracytoplasmic sperm injection (ICSI) \[[@B11]\].

Thereby, patients with a 45,X/46,XY karyotype or its variants reared as males who have Y microdeletions may, by means of assisted reproductive technologies, generate not only male offspring with sterility, but also individuals who are carriers of an unstable Y chromosome that may originate mosaicism with a 45,X cell line in the early stages of embryonic development leading to various anomalous phenotypes (TS, MGD and OT DSD) \[[@B13]\]. This is the case of the three patients with microdeletions from this sample reared as males, two with an apparently normal Y chromosome (cases 8 and 11) and one with a deletion apparently limited to Yq12 (case 6). In these three cases, as well as in case 13, in whom the structural alteration of the Y was more evident on karyotype, the presence of these abnormalities in euchromatic region should be taken into account in counseling regarding assisted reproduction.

Conclusions
===========

Absence of deletions in individuals with PGD suggests that the Y chromosome is intact, indicating that it is not likely that its instability in the gonads is one of the causes of this condition; further studies that aim to identify the etiology of this condition are needed. However, deletions identified in the second group indicate that mosaicism may be associated with Y chromosome abnormalities detectable only at the molecular level. If patients with mosaicism and Y microdeletions reared as males decide to undergo *in vitro* fertilization, Y chromosomes which tend to be unstable during cell division may be transmitted to offspring.
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